Fig. 3From: Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019Potential cost-savings (million €, %) through the splitting of single-tablet regimens and replacing all substance partners with generic antiretroviral drugs between 1/2017 and 2/2019Back to article page